Home
/
ARROWHEAD PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
ARROWHEAD PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ARROWHEAD PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Jun 30, 2018
$727.4K
Aug 7, 2018
Q2
2018
Mar 31, 2018
$650.1K
May 8, 2018
Q1
2018
Dec 31, 2017
$3.51M
Feb 9, 2018
Q3
2018
Jun 30, 2017
$9.34M
Aug 7, 2018
Q2
2018
Mar 31, 2017
$8.99M
May 8, 2018
Q1
2018
Dec 31, 2016
$4.37M
Feb 9, 2018
Q3
2017
Jun 30, 2016
$39.6K
Aug 3, 2017
Q2
2017
Mar 31, 2016
$43.8K
May 3, 2017
Q1
2017
Dec 31, 2015
$43.8K
Feb 6, 2017
Q3
2016
Jun 30, 2015
$123.8K
Aug 9, 2016
Q2
2016
Mar 31, 2015
$43.8K
May 10, 2016
Q1
2016
Dec 31, 2014
$170.8K
Feb 9, 2016
Q3
2015
Jun 30, 2014
$43.8K
Aug 4, 2015
Q2
2015
Mar 31, 2014
$43.8K
May 11, 2015
Q1
2015
Dec 31, 2013
$43.8K
Feb 9, 2015
Q3
2014
Jun 30, 2013
$43.8K
Aug 12, 2014
Q2
2014
Mar 31, 2013
$43.8K
May 6, 2014
Q1
2014
Dec 31, 2012
$159.0K
Feb 4, 2014
Q3
2013
Jun 30, 2012
$47.9K
Aug 7, 2013
Q2
2013
Mar 31, 2012
$31.3K
May 9, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
$264.03M
Feb 5, 2026
Q3
2025
Jun 30, 2025
$27.77M
Aug 7, 2025
Q2
2025
Mar 31, 2025
$542.71M
May 12, 2025
Q1
2026
Dec 31, 2024
$2.50M
Feb 5, 2026
Q3
2025
Jun 30, 2024
$0
Aug 7, 2025
Q2
2025
Mar 31, 2024
$0
May 12, 2025
Q1
2025
Dec 31, 2023
$3.55M
Feb 10, 2025
Q3
2024
Jun 30, 2023
$15.83M
Aug 8, 2024
Q2
2024
Mar 31, 2023
$146.27M
May 9, 2024
Q1
2024
Dec 31, 2022
$62.55M
Feb 6, 2024
Q3
2023
Jun 30, 2022
$32.41M
Aug 7, 2023
Q2
2023
Mar 31, 2022
$151.81M
May 2, 2023
Q1
2023
Dec 31, 2021
$27.44M
Feb 6, 2023
Q3
2022
Jun 30, 2021
$45.89M
Aug 4, 2022
Q2
2022
Mar 31, 2021
$32.81M
May 10, 2022
Q1
2022
Dec 31, 2020
$21.30M
Feb 2, 2022
Q3
2021
Jun 30, 2020
$27.38M
Aug 5, 2021
Q2
2021
Mar 31, 2020
$23.53M
May 4, 2021
Q1
2021
Dec 31, 2019
$29.46M
Feb 4, 2021
Q3
2020
Jun 30, 2019
$42.70M
Aug 5, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
$30.81M
Feb 5, 2026
Q3
2025
Jun 30, 2025
($175.24M)
Aug 7, 2025
Q2
2025
Mar 31, 2025
$370.45M
May 12, 2025
Q1
2026
Dec 31, 2024
($173.09M)
Feb 5, 2026
Q3
2025
Jun 30, 2024
($170.79M)
Aug 7, 2025
Q2
2025
Mar 31, 2024
($125.30M)
May 12, 2025
Q1
2025
Dec 31, 2023
($132.86M)
Feb 10, 2025
Q3
2024
Jun 30, 2023
($102.95M)
Aug 8, 2024
Q3
2023
Mar 31, 2023
$48.68M
Aug 7, 2023
Q2
2024
Mar 31, 2023
$48.68M
May 9, 2024
Q2
2023
Dec 31, 2022
($41.33M)
May 2, 2023
Q1
2024
Dec 31, 2022
($41.33M)
Feb 6, 2024
Q3
2023
Dec 31, 2022
($41.33M)
Aug 7, 2023
Q3
2023
Jun 30, 2022
($72.05M)
Aug 7, 2023
Q3
2023
Mar 31, 2022
$44.37M
Aug 7, 2023
Q2
2023
Mar 31, 2022
$44.37M
May 2, 2023
Q1
2023
Dec 31, 2021
($62.87M)
Feb 6, 2023
Q3
2023
Dec 31, 2021
($62.87M)
Aug 7, 2023
Q2
2023
Dec 31, 2021
($62.87M)
May 2, 2023
Q3
2022
Jun 30, 2021
($29.92M)
Aug 4, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
$40.81M
Feb 5, 2026
Q3
2025
Jun 30, 2025
($165.55M)
Aug 7, 2025
Q2
2025
Mar 31, 2025
$381.20M
May 12, 2025
Q1
2026
Dec 31, 2024
($161.41M)
Feb 5, 2026
Q3
2025
Jun 30, 2024
($176.14M)
Aug 7, 2025
Q2
2025
Mar 31, 2024
($126.19M)
May 12, 2025
Q1
2025
Dec 31, 2023
($136.55M)
Feb 10, 2025
Q3
2024
Jun 30, 2023
($102.70M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
$48.17M
May 9, 2024
Q1
2024
Dec 31, 2022
($42.13M)
Feb 6, 2024
Q3
2023
Jun 30, 2022
($72.91M)
Aug 7, 2023
Q2
2023
Mar 31, 2022
$41.55M
May 2, 2023
Q1
2023
Dec 31, 2021
($63.32M)
Feb 6, 2023
Q3
2022
Jun 30, 2021
($31.87M)
Aug 4, 2022
Q2
2022
Mar 31, 2021
($28.23M)
May 10, 2022
Q1
2022
Dec 31, 2020
($24.05M)
Feb 2, 2022
Q3
2021
Jun 30, 2020
($15.95M)
Aug 5, 2021
Q2
2021
Mar 31, 2020
($22.24M)
May 4, 2021
Q1
2021
Dec 31, 2019
($4.85M)
Feb 4, 2021
Q3
2020
Jun 30, 2019
$18.60M
Aug 5, 2020